AAV9.61 Serotype
Engineered AAV9 variant with 10-fold improved cardiac-to-liver transduction ratio for heart-targeted gene therapy.
| Tropism | Cardiac muscle (highly selective), reduced liver and skeletal muscle |
|---|
Characteristics
10-fold improved cardiac:liver transduction ratio. Capsid mutations reducing hepatic tropism. Enhanced cardiac specificity. Reduced off-target biodistribution.
Applications
Heart failure gene therapy. Cardiomyopathies. Cardiac-specific transgene expression with minimal hepatic exposure.
Sequence1 bp
Sign in to view the full sequence.
Sign inReferences
- 1.Pulicherla et al. (2011). Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol Ther — Pulicherla 2011 AAV9 Variants
